Twist Bioscience Corporation (Nasdaq: TWST) (“Twist”), a mid-cap growth and value biotech company, today announced the pricing of an upsized underwritten public offering of 3,125,000 shares of its common stock at a price to the public of $96.00 per share. All of the shares of common stock to be sol…
Explore more price target data and ratings for Twist Bioscience Corporation on the Forecasts tab, and track all previous and future analyst recommendations for Twist Bioscience Corporation in the dedicated News Flow.Select reference data provided by FactSet. Copyright © 2026 FactSet Research System…
Record Q3 revenue grew 23% year-over-year, driven by strong AI-enabled drug discovery and diagnostics. Raised fiscal 2026 guidance, expecting 21% growth and adjusted EBITDA breakeven in Q4. Triple-digit AI order growth is projected to continue into 2027, supported by robust customer demand and plat…
Q3 FY26 revenue rose 23% year-over-year to $118.4M, with gross margin improving to 52.8%. FY26 revenue guidance was raised to $456–$457M, and adjusted EBITDA breakeven is expected in Q4. Net loss was $35.1M, impacted by a prior-year gain from a business spin-out.Original document: Twist Bioscience…
Twist Bioscience reported third-quarter fiscal 2026 results with record revenue of $118.4 million, up more than 23% year-over-year, and a gross margin of 52.8%. The company posted a net loss of $35.1 million for the quarter and adjusted EBITDA of $(11.3) million. Twist raised its full-year 2026 rev…
Q3 FY26 revenue grew 23% YoY to $118.4M, beating guidance, with gross margin rising to 52.8% and adjusted EBITDA loss narrowing to $(11.3)M. DNA Synthesis & Protein Solutions and NGS Applications segments both posted strong growth. Adjusted EBITDA breakeven is expected in Q4 FY26.Original document…
Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, today announced financial results and business highlights for the third quarter fiscal 2026 ended June 30, 2026.Visit the Events and Presentations page of the Investor Relations section under the “Company” tab…
